Healthcare shares split as trial failures meet commercial progress

• Cochlear fell 11.88% as it faced a class action over its FY26 profit forecast.
• EMVision dropped 10.34% despite receiving a A$4.3 million research and development refund.
• TrivarX lost 9.09% after reporting a larger annual loss and warning that it needs more money.
• Firebrick rose 7.69% after approving a phased US pharmacy launch for Nasodine.